No Data
Frontage Narrows Q1 Loss
FRONTAGE (01521.HK) recorded a loss of approximately 0.9 million US dollars in the first quarter.
Globe News on April 28th | FRONTAGE (01521.HK) announced that for the three months ending March 31, 2025, the group recorded a net loss of approximately 0.9 million USD, compared to a net loss of approximately 1 million USD for the same period in 2024; revenue was about 57.1 million USD, a decrease of 10.6% from about 63.9 million USD in the same period of 2024. After deducting share-based compensation expenses, amortization of acquired intangible assets, and acquisition-related expenditures, the group's adjusted net profit was approximately 1.6 million USD, while it was about 2.2 million USD in the same period of 2024.
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
FRONTAGE: 2024 Annual Report
Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.
① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?
Hong Kong stocks in the pharmaceutical sector soared! Kai Medical surged more than 22%. Institutions claim that tariffs have "no impact" on the wave of Innovative Drugs going abroad.
① How do government policy support and the overseas expansion of Innovative Drugs become a new growth engine for Hong Kong stock pharmaceutical companies? ② Why does Zhongtai International believe that tariffs have limited impact on Innovative Drug companies?
Despite Hitting HK$1.67, Frontage Holdings Insiders Still Sold Too Soon
